The firm is testing the EGFR inhibitor BH-30643 in EGFR-mutated NSLC and the CLK inhibitor in certain blood cancers.

Waskyra, developed by Fondazione Telethon, is the first gene therapy that the FDA has approved from a non-profit applicant.

Researchers also discussed access barriers at the meeting, and a survey found distance was a major hindrance to CAR-T ...

Patient drug sensitivity profiles were linked to their genomic mutation profiles and could provide prognostic and survival data.

NEW YORK – A gene therapy using lentiviral particles to generate CAR T cells inside multiple myeloma patients has shown the ability to eliminate the small number of cancer cells in the bone marrow ...

Writing in JAMA, regulators said randomized controlled trials with a survival or time-to-event endpoint would be expected for approval of a new CAR T-cell therapy.